Walder Wyss advised Distalmotion on its Series F financing round

Distalmotion, an international medical device company based in Lausanne, successfully closed the first tranche of its USD 150 million Series F financing round led by Revival Healthcare Capital.

Founded and based in Lausanne, Distalmotion has the mission to remove the complexity out of robotic surgery in order to give all patients in general surgery, gynecology and urology access to best-in-class minimally invasive care. Dexter, company’s robotic platform, is in day-to-day clinical use in Europe, successfully treating patients across a multitude of complex and high-volume procedures. The funding will enable the way for US Food and Drug Administration (FDA) approval and to continue acceleration of clinical experience in Europe.

Walder Wyss advised Distalmotion in connection with the transaction. The team was led by partner Alex Nikitine (corporate/m&a, pictured left) and managing associate Dimitrios Berger (corporate/m&a, pictured right) and further included Anaëlle Genoud (finance, senior associate), Valentine Schnyder (corporate/m&a, senior associate), Camille Tistounet (corporate/m&a, associate) and Pascale Friolet (corporate/m&a, trainee lawyer).